Search results

Found 5,004 pages
AUTHOR: Selina McKee

Your search yielded no results

  • Check if your spelling is correct.
  • Remove quotes around phrases to search for each word individually. bike shed will often show more results than "bike shed".
  • Consider loosening your query with OR. bike OR shed will often show more results than bike shed.

Astellas bags orphan drug status for AML drug

Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/astellas_bags_orphan_drug_status_for_aml_drug_1218291

Artios in-licenses experimental cancer drug

Cambridge, UK-based Artios Pharma has exercised an option to in-license the first nuclease drug development programme from its research alliance with Masaryk University in the Czech Republic. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/artios_in-licenses_experimental_cancer_drug_1225943

NHS in “never-ending winter”

Warning bells for the NHS are ringing again after the latest performance data showed the highest number of emergency admissions since records began and more patients than ever before waiting more than four hours for treatment. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/nhs_in_never-ending_winter_1231697

Allergan announces job cull to cut costs

Allergan has unveiled plans to trim more than 1,000 jobs from its workforce in a bid to reduce costs and prepare for increased generic competition this year. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/allergan_announces_job_cull_to_cut_costs_1215222

Incyte/MSD's immunotherapy combo fails in Phase III

A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/incytemsds_immunotherapy_combo_fails_in_phase_iii_1230900

Green light for Perjeta/Herceptin combo

Roche group Genentech has secured approval of Perjeta in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment of a specific type of early breast cancer in the US. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/green_light_for_perjetaherceptin_combo_1214829

Novo files N8-GP in the US and EU

Novo Nordisk has filed regulatory applications in the US and European Union seeking approval to market N8-GP for the treatment of haemophilia - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/novo_files_n8-gp_in_the_us_and_eu_1224736

Final NHS nod for Janssen’s Imbruvica

Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/final_nhs_nod_for_janssens_imbruvica_1219708

Boehringer ends development of Alzheimer’s candidate

Boehringer Ingelheim is ending development of BI 409306 in Alzheimer's disease on disappointing mid-stage trial data. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/boehringer_ends_development_of_alzheimers_candidate_1221438

BI snaps up OSE’s novel checkpoint inhibitor

Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/bi_snaps_up_oses_novel_checkpoint_inhibitor_1230452

Latest jobs

View all

What job are you looking for?

This field is required.

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download